Table 1 Patient demographics and baseline characteristics
From: Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial
Items | Tianzhi (n = 232) | Donepezil (n = 233) | Placebo (n = 55) |
|---|---|---|---|
Gender, male/female | 154/78 | 149/84 | 35/20 |
Race, han/other | 226/6 | 233/0 | 54/1 |
Age, mean (SD) | 64.72 (9.18) | 64.31 (9.99) | 63.95 (9.15) |
Education | |||
 Primary school, N (%) | 82 (35.34) | 85 (36.48) | 23 (41.82) |
 Middle school and above, N (%) | 150 (64.66) | 148 (63.52) | 32 (58.18) |
Smoking history, (yes/no) | 97/134 | 96/136 | 24/31 |
Drinking history, (yes/no) | 80/151 | 69/163 | 18/37 |
Neuropsychological score, Mean (SD) | |||
 VADAS-cog | 52.64 (10.59) | 53.29 (10.17) | 52.22 (11.36) |
 MMSE | 20.56 (3.36) | 20.56 (3.24) | 20.51 (2.97) |
 TMT-A | 112.05 (41.03) | 113.26 (45.52) | 124.69 (47.46) |
 TMT-B | 208.42 (87.42) | 209.42 (88.92) | 235.83 (71.05) |
 ADL | 15.15 (9.62) | 14.66 (9.76) | 14.87 (8.81) |
 CDT | 2.48 (1.21) | 2.53 (1.20) | 2.35 (1.27) |
 NPI | 5.31 (5.52) | 5.35 (4.91) | 5.40 (5.51) |